{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:13:30Z","timestamp":1761560010885},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,12,15]],"date-time":"2013-12-15T00:00:00Z","timestamp":1387065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00296-013-2913-y","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T08:20:42Z","timestamp":1387009242000},"page":"793-801","source":"Crossref","is-referenced-by-count":12,"title":["Candidate\u2019s single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis"],"prefix":"10.1007","volume":"34","author":[{"given":"Ruxandra","family":"Schiotis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerea","family":"Bartolom\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Szczypiorska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Font","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Tejedor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Artieda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Mulero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Buzoianu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Collantes-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,15]]},"reference":[{"key":"2913_CR1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/art.1780210603","volume":"21","author":"V Wright","year":"1978","unstructured":"Wright V (1978) Seronegative polyarthritis: a unified concept. Arthritis Rheum 21:619\u2013633","journal-title":"Arthritis Rheum"},{"key":"2913_CR2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"J Braun","year":"1995","unstructured":"Braun J, Bollow M, Neure L et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499\u2013505","journal-title":"Arthritis Rheum"},{"key":"2913_CR3","doi-asserted-by":"crossref","first-page":"i85","DOI":"10.1136\/ard.59.suppl_1.i85","volume":"59","author":"J Braun","year":"2000","unstructured":"Braun J, Xiang J, Brandt J et al (2000) Treatment of spondyloarthropathies with antibodies against tumor necrosis factor \u03b1: first clinical and laboratory experiences. Ann Rheum Dis 59:i85\u2013i89","journal-title":"Ann Rheum Dis"},{"key":"2913_CR4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrrheum.2009.258","volume":"6","author":"W Maksymowych","year":"2010","unstructured":"Maksymowych W (2010) Disease modification in ankylosing spondylitis. Nat Rev Rheumatol 6:75\u201381","journal-title":"Nat Rev Rheumatol"},{"key":"2913_CR5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582\u2013591","journal-title":"Arthritis Rheum"},{"key":"2913_CR6","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, van der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230\u20133236","journal-title":"Arthritis Rheum"},{"key":"2913_CR7","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136\u20132146","journal-title":"Arthritis Rheum"},{"key":"2913_CR8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/ard.2011.154799","volume":"71","author":"J Braun","year":"2012","unstructured":"Braun J, Deodhar A, Inman RD et al (2012) Golimumab administered subcutaneously every 4\u00a0weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 71:661\u2013667","journal-title":"Ann Rheum Dis"},{"key":"2913_CR9","first-page":"1751","volume":"32","author":"JC Davis Jr","year":"2005","unstructured":"Davis JC Jr, van der Heijde DM, Dougados M et al (2005) Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 32:1751\u20131754","journal-title":"J Rheumatol"},{"key":"2913_CR10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63:665\u2013670","journal-title":"Ann Rheum Dis"},{"key":"2913_CR11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger N, van der Heijde D, Inman RD et al (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70:973\u2013981","journal-title":"Ann Rheum Dis"},{"key":"2913_CR12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","volume":"36","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Claudepierre P, Wordsworth P et al (2009) Effectiveness, safety, and predictors of good clinical response in 1,250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36:801\u2013810","journal-title":"J Rheumatol"},{"key":"2913_CR13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kep422","volume":"49","author":"PA Lord","year":"2010","unstructured":"Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL (2010) Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 49:563\u2013570","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"2913_CR14","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","volume":"20","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E et al (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 20(13):R94","journal-title":"Arthritis Res Ther"},{"key":"2913_CR15","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1756-185X.2012.01817.x","volume":"15","author":"M Can","year":"2012","unstructured":"Can M, Ayd\u0131n SZ, Ni\u011fdelio\u011flu A, Atag\u00fcnd\u00fcz P, Direskeneli H (2012) Conventional DMARD therapy (methotrexate\u2013sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: a real-life experience. Int J Rheum Dis 15:526\u2013530","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"2913_CR16","first-page":"CD004524","volume":"28","author":"J Chen","year":"2013","unstructured":"Chen J, Veras MM, Liu C, Lin J (2013) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 28(2):CD004524","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2913_CR17","first-page":"CD004800","volume":"18","author":"J Chen","year":"2005","unstructured":"Chen J, Liu C (2005) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 18(2):CD004800","journal-title":"Cochrane Database Syst Rev"},{"key":"2913_CR18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/art.21588","volume":"53","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Brandt J, Listing J et al (2005) Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 53:856\u2013863","journal-title":"Arthritis Rheum"},{"key":"2913_CR19","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","volume":"50","author":"X Baraliakos","year":"2011","unstructured":"Baraliakos X, Listing J, Fritz C et al (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8\u00a0years-early clinical response predicts long-term outcome. J Rheumatol (Oxford) 50:1690\u20131699","journal-title":"J Rheumatol (Oxford)"},{"key":"2913_CR20","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3899\/jrheum.110130","volume":"38","author":"DA Poddubnyy","year":"2011","unstructured":"Poddubnyy DA, M\u00e4rker-Hermann E, Kaluza-Schilling W et al (2011) Relation of HLA-B27, tumor necrosis factor-\u03b1 promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis\u2014a comprehensive genotype-phenotype analysis from an observational cohort. J Rheumatol 38:2436\u20132441","journal-title":"J Rheumatol"},{"key":"2913_CR21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","volume":"46","author":"M Seitz","year":"2007","unstructured":"Seitz M, Wirthmu\u00a8 ller U, Moller B, Villiger PM (2007) The \u2212308 tumour necrosis factor-gene polymorphismpredicts therapeutic response to TNF-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 46:93\u201396","journal-title":"Rheumatology"},{"key":"2913_CR22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/rheumatology\/kem084","volume":"46","author":"E Collantes","year":"2007","unstructured":"Collantes E, Zarco P, Munoz E et al (2007) Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatology (Oxford) 46:1309\u20131315","journal-title":"Rheumatology (Oxford)"},{"key":"2913_CR23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/rheumatology\/keq253","volume":"50","author":"R Schiotis","year":"2011","unstructured":"Schiotis R, Font P, Escudero E et al (2011) Usefulness of a centralized system of data collection for the development of an international multicentre registry of spondyloarthritis. Rheumatology (Oxford) 50:132\u2013136","journal-title":"Rheumatology (Oxford)"},{"key":"2913_CR24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden Van der","year":"1984","unstructured":"Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"2913_CR25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1101\/sqb.2003.68.69","volume":"68","author":"JB Fan","year":"2003","unstructured":"Fan JB, Oliphant A, Shen R et al (2003) Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 68:69\u201378","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"2913_CR26","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1158\/1055-9965.EPI-06-0219","volume":"15","author":"RA Paynter","year":"2006","unstructured":"Paynter RA, Skibola DR, Skibola CF et al (2006) Accuracy of multiplexed Illumina platform-based single-nucleotide polymorphism genotyping compared between genomic and whole genome amplified DNA collected from multiple sources. Cancer Epidemiol Biomarkers Prev 15:2533\u20132536","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2913_CR27","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng1646","volume":"37","author":"D Reich","year":"2005","unstructured":"Reich D, Patterson N, De Jager PL et al (2005) A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nat Genet 37:1113\u20131118","journal-title":"Nat Genet"},{"issue":"21","key":"2913_CR28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"15","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 15(21):263\u2013265","journal-title":"Bioinformatics"},{"key":"2913_CR29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, \u00d8stergaard M, Krogh NS et al (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72:1149\u20131155","journal-title":"Ann Rheum Dis"},{"key":"2913_CR30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0952-7915(98)80163-5","volume":"10","author":"H Okamura","year":"1998","unstructured":"Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K (1998) Regulation of interferon-_ production by IL-12 and IL-18. Curr Opin Immunol 10:259\u2013264","journal-title":"Curr Opin Immunol"},{"key":"2913_CR31","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/art.24750","volume":"60","author":"W Jager de","year":"2009","unstructured":"de Jager W, Vastert SJ, Beekman JM et al (2009) Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60:2782\u20132793","journal-title":"Arthritis Rheum"},{"key":"2913_CR32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/ng.102","volume":"40","author":"KA Hunt","year":"2008","unstructured":"Hunt KA, Zhernakova A, Turner G et al (2008) Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 40:395\u2013402","journal-title":"Nat Genet"},{"key":"2913_CR33","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ajhg.2008.03.016","volume":"82","author":"A Zhernakova","year":"2008","unstructured":"Zhernakova A, Festen EM, Franke L et al (2008) Genetic analysis of innate immunity in Crohn\u2019s disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet 82:1202\u20131210","journal-title":"Am J Hum Genet"},{"key":"2913_CR34","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/keq102","volume":"49","author":"L Eder","year":"2010","unstructured":"Eder L, Chandran V, Ueng J et al (2010) Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 49:1367\u20131373","journal-title":"Rheumatology (Oxford)"},{"key":"2913_CR35","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1002\/art.21285","volume":"52","author":"TR Radstake","year":"2005","unstructured":"Radstake TR, Sweep FC, Welsing P et al (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52:3020\u20133029","journal-title":"Arthritis Rheum"},{"key":"2913_CR36","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.leu.2402545","volume":"16","author":"M Lauten","year":"2002","unstructured":"Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M (2002) Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumor necrosis factor and the interleukin-10 genes. Leukemia 16:1437\u20131442","journal-title":"Leukemia"},{"key":"2913_CR37","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood.V92.10.3943","volume":"92","author":"PG Middleton","year":"1998","unstructured":"Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM (1998) Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 92:3943\u20133948","journal-title":"Blood"},{"key":"2913_CR38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3899\/jrheum.090566","volume":"37","author":"B Paz de","year":"2010","unstructured":"de Paz B, Alperi-L\u00f3pez M, Ballina-Garc\u00eda FJ, Prado C, Mozo L, Guti\u00e9rrez C, Su\u00e1rez A (2010) Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis-association with clinical response to glucocorticoids. J Rheumatol 37:503\u2013511","journal-title":"J Rheumatol"},{"key":"2913_CR39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","volume":"10","author":"H Wajant","year":"2003","unstructured":"Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45\u201365","journal-title":"Cell Death Differ"},{"key":"2913_CR40","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","volume":"83","author":"M Grell","year":"1995","unstructured":"Grell M, Douni E, Wajant H et al (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80\u00a0kDa tumor necrosis factor receptor. Cell 83:793\u2013802","journal-title":"Cell"},{"key":"2913_CR41","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4049\/jimmunol.176.2.1026","volume":"176","author":"EY Kim","year":"2006","unstructured":"Kim EY, Priatel JJ, Teh SJ, Teh HS (2006) TNF receptor type 2 (p75) Functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 176:1026\u20131035","journal-title":"J Immunol"},{"key":"2913_CR42","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/art.1780351008","volume":"35","author":"AP Cope","year":"1992","unstructured":"Cope AP, Aderka D, Doherty M et al (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 35:1160\u20131169","journal-title":"Arthritis Rheum"},{"key":"2913_CR43","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/art.1780351009","volume":"35","author":"BW Deleuran","year":"1992","unstructured":"Deleuran BW, Chu C-Q, Field M et al (1992) Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor. Arthritis Rheum 35:1170\u20131178","journal-title":"Arthritis Rheum"},{"key":"2913_CR44","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.humimm.2004.06.010","volume":"65","author":"B Tolusso","year":"2004","unstructured":"Tolusso B, Sacco S, Gremese E, La Torre G, Tomietto P, Ferraccioli GF (2004) Relationship between the tumor necrosis factor receptor II (TNF-RII) gene polymorphism and sTNF-RII plasma levels in healthy controls and in rheumatoid arthritis. Hum Immunol 65:1420\u20131426","journal-title":"Hum Immunol"},{"key":"2913_CR45","doi-asserted-by":"crossref","first-page":"R1227","DOI":"10.1186\/ar1816","volume":"7","author":"JR Glossop","year":"2005","unstructured":"Glossop JR, Dawes PT, Nixon NB, Mattey DL (2005) Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther 7:R1227\u2013R1234","journal-title":"Arthritis Res Ther"},{"key":"2913_CR46","first-page":"1847","volume":"29","author":"M Fabris","year":"2002","unstructured":"Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G (2002) Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. Rheumatology 29:1847\u20131850","journal-title":"Rheumatology"},{"key":"2913_CR47","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/ard.2010.138883","volume":"70","author":"SJ Pedersen","year":"2011","unstructured":"Pedersen SJ, S\u00f8rensen IJ, Garnero P et al (2011) ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF\u03b1 inhibitors. Ann Rheum Dis 70:1375\u20131381","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2913-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-013-2913-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2913-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T03:45:05Z","timestamp":1597203905000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-013-2913-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,15]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2913"],"URL":"https:\/\/doi.org\/10.1007\/s00296-013-2913-y","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,15]]}}}